Título :	Produção da proteína ECA2 recombinante para utilização no desenvolvimento de anticorpos monoclonais com fins terapêuticos e diagnósticos da Covid-19
Autor :	Morais, Cristiana Soares dos Santos de
Orientador(es)::	Nicola, André Moraes
Assunto::	Covid-19 Anticorpos monoclonais Enzima conversora da angiotensina Proteína recombinante
Fecha de publicación :	13-sep-2023
Data de defesa::	11-oct-2022
Citación :	MORAIS, Cristiana Soares dos Santos de. Produção da proteína ECA2 recombinante para utilização no desenvolvimento de anticorpos monoclonais com fins terapêuticos e diagnósticos da Covid-19. 2022. 63 f., il. Dissertação (Mestrado em Patologia Molecular) — Universidade de Brasília, Brasília, 2022.
Abstract:	SARS-CoV-2 is the etiologic agent of COVID-19 pandemic, which binds to cell surface receptor Angiotensin-converting Enzyme 2 (ACE2) to begin viral replication. Until the moment, there is no specific treatment for the disease and available diagnostic methods vary in costs, sensibility, and specificity. In this context, specific anti-SARS-CoV-2 monoclonal antibodies development is still of great relevance and to test their neutralization capacity for each new variant will continue to be essential. In this study, we have transiently expressed soluble recombinant ACE2 in different mammalian cell lines HEK293F and ExpiCHO to apply in development of human monoclonal antibodies to therapeutic and diagnostic uses in COVID-19. The productivity of recombinant protein was high for both cell lines (1,8 mg/mL and 3,4 mg/mL, respectively), but they showed different glycosylation patterns. The binding capacity of the expressed protein to Spike protein of original virus and variants was confirmed in ELISA and flow cytometry. And the applicability of recombinant protein in inhibition assays with Alpha and Gama variants was validated by flow cytometry, with inhibitory capacity superior of 90% for three scFv clones.
metadata.dc.description.unidade:	Faculdade de Medicina (FM)
Descripción :	Dissertação (mestrado) — Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Patologia Molecular, 2022.
metadata.dc.description.ppg:	Programa de Pós-Graduação em Patologia Molecular
Aparece en las colecciones:	Teses, dissertações e produtos pós-doutorado UnB - Covid-19

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.